Published in Mov Disord on May 01, 1997
Citalopram to Enhance Cognition in HD (CIT-HD) | NCT00271596
Huntington's disease: can mice lead the way to treatment? Neuron (2011) 1.71
Symptomatic treatment of Huntington disease. Neurotherapeutics (2008) 1.08
Patterns of serotonergic antidepressant usage in prodromal Huntington disease. Psychiatry Res (2012) 0.81
Treatment of huntington disease. Curr Treat Options Neurol (2013) 0.81
Cell Therapy Strategies vs. Paracrine Effect in Huntington's Disease. J Mov Disord (2014) 0.78
Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases? Front Psychiatry (2015) 0.77
Six psychotropics for pre-symptomatic & early Alzheimer's (MCI), Parkinson's, and Huntington's disease modification. Neural Regen Res (2016) 0.76
Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord (2013) 0.75
Three-dimensional model of purple membrane obtained by electron microscopy. Nature (1975) 13.28
Molecular structure determination by electron microscopy of unstained crystalline specimens. J Mol Biol (1975) 7.56
MRC image processing programs. J Struct Biol (1996) 6.91
Detection of Huntington's disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry (2007) 5.49
Electron-crystallographic refinement of the structure of bacteriorhodopsin. J Mol Biol (1996) 4.96
Path of the polypeptide in bacteriorhodopsin. Proc Natl Acad Sci U S A (1980) 4.76
Talk is cheap: measuring drinking outcomes in clinical trials. J Stud Alcohol (2000) 4.75
The structure of the purple membrane from Halobacterium hallobium: analysis of the X-ray diffraction pattern. J Mol Biol (1975) 4.64
Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group. Neurology (1990) 4.41
A molecular basis for MHC class II--associated autoimmunity. Science (1988) 3.75
Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 3.68
The binding of labelled tetrodotoxin to non-myelinated nerve fibres. J Physiol (1972) 3.60
Three-dimensional structure of tosyl-alpha-chymotrypsin. Nature (1967) 3.57
Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet (1994) 3.56
Electron diffraction analysis of structural changes in the photocycle of bacteriorhodopsin. EMBO J (1993) 3.54
Huntington disease: clinical care and evaluation. Neurology (1979) 3.54
Effect of low-level body burdens of lead on the mental development of children: limitations of meta-analysis in a review of longitudinal data. Arch Environ Health (1992) 3.42
Projection structure of rhodopsin. Nature (1993) 3.41
Three-dimensional structure determination by electron microscopy of two-dimensional crystals. Prog Biophys Mol Biol (1982) 3.14
The purple membrane from Halobacterium halobium. Annu Rev Biophys Bioeng (1977) 2.90
Living alone after myocardial infarction. Impact on prognosis. JAMA (1992) 2.88
Molecular mechanism of vectorial proton translocation by bacteriorhodopsin. Nature (2000) 2.88
Detective quantum efficiency of electron area detectors in electron microscopy. Ultramicroscopy (2009) 2.75
Structure of crystalline -chymotrypsin. II. A preliminary report including a hypothesis for the activation mechanism. J Mol Biol (1968) 2.72
Involvement of Sonic hedgehog (Shh) in mouse embryonic lung growth and morphogenesis. Development (1997) 2.61
Intratracheal instillation as an exposure technique for the evaluation of respiratory tract toxicity: uses and limitations. Toxicol Sci (2000) 2.54
Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet (1995) 2.50
Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology (2000) 2.49
Homozygotes for Huntington's disease. Nature (1987) 2.40
Evidence from normal expression and targeted misexpression that bone morphogenetic protein (Bmp-4) plays a role in mouse embryonic lung morphogenesis. Development (1996) 2.38
Identification of human adenovirus early region 1 products by using antisera against synthetic peptides corresponding to the predicted carboxy termini. J Virol (1983) 2.35
Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18
Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17
Clinical markers of early disease in persons near onset of Huntington's disease. Neurology (2001) 2.11
The binding of labelled saxitoxin to the sodium channels in nerve membranes. J Physiol (1973) 2.10
Digital incremental techniques applied to spirometry. Proc R Soc Med (1977) 2.10
Effects of exposure to slate dust in North Wales. Br J Ind Med (1980) 2.09
The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08
Evidence that tetrodotoxin and saxitoxin act at a metal cation binding site in the sodium channels of nerve membrane. Proc Natl Acad Sci U S A (1974) 2.06
Orthorhombic two-dimensional crystal form of purple membrane. Proc Natl Acad Sci U S A (1980) 2.00
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol (2000) 2.00
On-off response. Clinical and biochemical correlations during oral and intravenous levodopa administration in parkinsonian patients. Neurology (1975) 1.96
Current activities at the Centers for Disease Control and Prevention's National Diabetes Laboratory. Diabetes Technol Ther (1999) 1.95
Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94
Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol (2001) 1.91
Analysis of electron microscope images and electron diffraction patterns of thin crystals of phi 29 connectors in ice. J Mol Biol (1994) 1.90
Predicting verbal memory decline following anterior temporal lobectomy (ATL). Neurology (2003) 1.89
Structure of crystalline alpha-chymotrypsin. 3. Crystallographic studies of substrates and inhibitors bound to the active site of alpha-chymotrypsin. J Mol Biol (1969) 1.87
Predictive accuracy and explained variation in Cox regression. Biometrics (2000) 1.86
Prevalence of sleep apnea syndrome among patients with essential hypertension. Am Heart J (1984) 1.83
Coronary angioplasty versus medical therapy for angina. Health service costs based on the second Randomized Intervention Treatment of Angina (RITA-2) trial. Eur Heart J (2002) 1.83
Quantitative functional measures in MS: what is a reliable change? Neurology (2002) 1.81
Weight loss in early stage of Huntington's disease. Neurology (2002) 1.79
A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77
Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord (1990) 1.76
Public-private interaction in pharmaceutical research. Proc Natl Acad Sci U S A (1996) 1.76
A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clin Neuropharmacol (2000) 1.75
Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery. AJNR Am J Neuroradiol (2001) 1.73
Specific labelling of the protein and lipid on the extracellular surface of purple membrane. J Mol Biol (1978) 1.71
Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology (2008) 1.70
Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology (2010) 1.67
Morphometry of the human pulmonary arterial tree. Circ Res (1973) 1.65
Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med (2001) 1.65
Electron imaging with Medipix2 hybrid pixel detector. Ultramicroscopy (2006) 1.65
Structure of crystalline alpha-chymotrypsin. IV. The structure of indoleacryloyl-alpha-chyotrypsin and its relevance to the hydrolytic mechanism of the enzyme. J Mol Biol (1970) 1.64
Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology (1996) 1.64
Electronic detectors for electron microscopy. Curr Opin Struct Biol (2007) 1.63
Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology (2010) 1.63
Etiology and clinical course of missed spine fractures. J Trauma (1987) 1.62
A portable bellows spirometer and timing unit for the measurement of respiratory function. Med Biol Eng (1968) 1.61
Experimental observation of the improvement in MTF from backthinning a CMOS direct electron detector. Ultramicroscopy (2009) 1.60
Evidence for anticipation and association of deletion size with severity in facioscapulohumeral muscular dystrophy. The FSH-DY Group. Ann Neurol (1996) 1.60
Evaluation of workers exposed to elemental mercury using quantitative tests of tremor and neuromuscular functions. Am Ind Hyg Assoc J (1978) 1.58
N-methyl-D-aspartate antagonists in the treatment of Parkinson's disease. Arch Neurol (1991) 1.58
Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology (2006) 1.57
Three-dimensional structure of halorhodopsin at 7 A resolution. J Mol Biol (1995) 1.57
Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs. Neurology (1981) 1.57
Solubilization of a specific tetrodotoxin-binding component from garfish olfactory nerve membrane. Biochemistry (1972) 1.56
Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys (1996) 1.56
Immunohistochemical determination of estrogen and progesterone receptor status in breast cancer. Am J Clin Pathol (1993) 1.55
Identification of Salmonella somatic and flagellar antigens by modified serological methods. Appl Environ Microbiol (1990) 1.54
Images of paraffin monolayer crystals with perfect contrast: minimization of beam-induced specimen motion. Ultramicroscopy (2010) 1.53
Arrangement of cytochrome oxidase molecules in two-dimensional vesicle crystals. J Mol Biol (1977) 1.50
Electron diffraction analysis of the M412 intermediate of bacteriorhodopsin. Biophys J (1986) 1.47
Protein conformational changes in the bacteriorhodopsin photocycle. J Mol Biol (1999) 1.45
The oral cavity in Crohn's disease. J Pediatr (2001) 1.44
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology (2003) 1.44
Medication use among children with asthma in East Harlem. Pediatrics (2000) 1.43
A common mucosal immunologic system involving the bronchus, breast and bowel. Adv Exp Med Biol (1978) 1.42
Caudate blood flow and volume are reduced in HIV+ neurocognitively impaired patients. Neurology (2006) 1.42
A multiple sclerosis cluster associated with a small, north-central Illinois community. Arch Environ Health (2002) 1.41
ALS defeats gabapentin: reflections on another failed treatment. Neurology (2001) 1.41
Huntington's disease in Venezuela: neurologic features and functional decline. Neurology (1986) 1.39
Images of purple membrane at 2.8 A resolution obtained by cryo-electron microscopy. J Mol Biol (1988) 1.38
Psychiatric syndromes in Huntington's disease. Am J Psychiatry (1983) 1.38
Assessment of knowledge of AIDS and beliefs about AIDS prevention among adolescents. AIDS Educ Prev (1990) 1.38
Comparison of the new miniature Wright peak flow meter with the standard Wright peak flow meter. Thorax (1979) 1.38
Structural comparison of native and deoxycholate-treated purple membrane. Biophys J (1985) 1.38